Powder: -20°C for 3 years | In solvent: -80°C for 1 year
J-113863 是选择性的 CCR1 (CD18)拮抗剂,有抗炎作用,对人和小鼠 CCR1受体的 IC50值分别为 0.9 和 5.8 nM。它是人 CCR3的强效拮抗剂,还是小鼠 CCR3的弱效拮抗剂,IC50分别为 0.58 和 460 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 557 | 现货 | ||
2 mg | ¥ 811 | 现货 | ||
5 mg | ¥ 1,320 | 现货 | ||
10 mg | ¥ 1,670 | 现货 | ||
25 mg | ¥ 3,270 | 现货 | ||
50 mg | ¥ 4,780 | 现货 | ||
100 mg | ¥ 6,820 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,730 | 现货 |
产品描述 | J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect. J-113863 is a potent and selective CCR1 (CD18) antagonist with IC50 values of 0.9 nM and 5.8 nM for human and mouse CCR1 receptors, respectively. |
靶点活性 | CCR3:0.58 nM (IC50, Human CCR3), CCR3:460 nM (IC50, Mouse CCR3), CCR1:0.9 nM (IC50, Human CCR1), CCR1:5.8 nM (IC50, Mouse CCR1) |
体外活性 | The chemotaxis of the following cells were inhibited by J-113863. Modified Vaccinia virus Ankara (MVA) but not MVA and vaccinia virus (VACV) infected MH-S cells increase the expression of the CXCR2 acting chemokine CXCL2. MH-S cells constitutively produce CCL2 and CCR1 acting chemokines CCL3, CCL5 and CCL9. Consequently, supernatants of mock treated and virus infected MH-S cells induce chemotaxis of murine promyelocyte MPRO cells and human monocytic THP-1 cells at the same level. However, supernatants of MVA infected MH-S cells significantly increase chemotaxis of the CCR2 deficient human monocytic cell line U-937. |
体内活性 | J-113863 treatment improves paw inflammation and joint damage, and dramatically decreases cell infiltration into joints in arthritic mice. |
分子量 | 655.44 |
分子式 | C30H37Cl2IN2O2 |
CAS No. | 353791-85-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 6.56 mg/mL (10 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.5257 mL | 7.6285 mL | 15.2569 mL | 38.1423 mL |
5 mM | 0.3051 mL | 1.5257 mL | 3.0514 mL | 7.6285 mL | |
10 mM | 0.1526 mL | 0.7628 mL | 1.5257 mL | 3.8142 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
J-113863 353791-85-2 Immunology/Inflammation Microbiology/Virology CCR Inhibitor inhibit rheumatoid CCR1 CCR3 J 113863 CC chemokine receptor Chemotaxis collagen arthritis J113863 CD18 anti-inflammatory inhibitor